What You Should Know:
- PathAI Diagnostics, formerly Poplar Healthcare, a leading laboratory services company, today unveiled the world’s first AI-assisted laboratory-developed test for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).
- MASLD and MASH are posing an escalating healthcare challenge, affecting millions of individuals worldwide – as many as 37.8% of the global adult population suffers from some form of MASLD, a potential precursor to severe conditions such as cirrhosis and liver cancer.
AI-Driven Tests for Improving MASLD/MASH Detection
While the gold standard for MASLD/MASH scoring is liver biopsy, the scoring provided by pathologists can exhibit variability. In fact, there can be as much as a 30% disagreement in MASH diagnosis between pathologists, and intra-observer variability can reach up to 41% for the same case. Accurate scoring and staging are paramount, as each fibrosis stage corresponds to approximately a two-fold increase in liver-related mortality. In response to this need, PathAI Diagnostics today announced AI.Dx MASH, a laboratory-developed test which provides AI-assisted histologic scoring that supports expert pathologists with enhanced insights for liver biopsy reporting.
In order to better tackle this growing issue, PathAI Diagnostics developed AI.Dx MASH, a laboratory developed test, which provides AI-assisted histologic scoring that supports expert pathologists with enhanced insights for liver biopsy reporting. “We are excited to bring the world’s first AI-assisted Laboratory Developed Test for MASH to market,” said Jim Sweeney, President of PathAI Diagnostics. “The tool uses our deep expertise in AI-powered pathology coupled with our world-class diagnostics laboratory to improve patient outcomes through AI-assisted histologic scoring for MASH.”
This groundbreaking tool utilizes an AI algorithm that has been proven to significantly reduce inter- and intra-operator variability in CRN scoring. Moreover, AI.Dx MASH reports include image overlays and quantitation, offering a comprehensive view of steatosis, lobular inflammation, hepatocyte ballooning, and fibrosis, thus facilitating more accurate diagnosis and staging.8-11
